J Thorac Oncol 2015 Oct;10(10):1458-67
*Thoracic Oncology Unit, Arnaud de Villeneuve Hospital/CHRU Montpellier, Montpellier, France; †Department of Pneumology, University Hospital, KU Leuven, Leuven, Belgium; ‡Medical Oncology, European Institute of Oncology, Milan, Italy; §Division of Hematology and Hematologic Malignancies, University of Utah Huntsman Cancer Institute, Salt Lake City, Utah; ¶Department of Thoracic Oncology, Hospital Grosshansdorf, Grosshansdorf, Germany; ‖Department of Respiratory Medicine, Ziekenhuis Oost Limburg, Genk and LCRP Oncology Cluster, University of Hasselt, Hasselt, Belgium; #Department of Medical Oncologie, ICO R. Gauducheau, St-Herblain, France; **Department of Oncology, University Hospital S. Maria della misericordia, Udine, Italy; ††Nottingham University Hospitals NHS Trust, Nottingham, United Kingdom; ‡‡Northwest Lung Centre, University Hospitals of South Manchester, Manchester, United Kingdom; §§Thoracic Oncology-Pneumology Service, André Renard Clinic, Herstal, Belgium; ¶¶Clinic of Thoracic Surgery, Waldburg-Zeil Clinic, Wangen im Allgäu, Germany; and ‖‖GSK Vaccines, Rixensart, Belgium.